Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agents Therapy from the ACTG A5336 Study.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of clinical pharmacology"
DOI: 10.1002/jcph.1930
Abstract: Ruxolitinib is an FDA-approved orally administered Janus kinase (JAK 1/2) inhibitor that reduces cytokine-induced inflammation. As part of a randomized, Phase 2, open label trial, ruxolitinib (10 mg, bid) was administered to HIV+ , virologically… read more here.
Keywords: pharmacokinetics ruxolitinib; antiretroviral agents; study; ruxolitinib hiv ... See more keywords